Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to shrink Hard-to-Treat neuroendocrine tumors

NCT ID NCT06157827

Disease control Sponsor: Nanjing Leads Biolabs Co.,Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called LBL-024 combined with standard chemotherapy (etoposide plus platinum) as a first treatment for people with advanced neuroendocrine carcinoma. About 178 adults aged 18-75 will take part to see if the combination is safe and helps shrink tumors. The trial is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LBL-024 combined with etoposide and platinum chemotherapy
What this could lead to
If successful, this could offer a new first-line treatment option for advanced neuroendocrine carcinoma, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so the benefits are uncertain. The combination may cause significant side effects, and results may not apply to all patients.
Why investors are watching

Nanjing Leads Biolabs is testing its drug LBL-024 with standard chemotherapy as a first treatment for advanced neuroendocrine carcinoma, a rare cancer with few options. For a small company, this mid-stage trial is a key test of whether its drug works and is safe, and the result could shape its future.

If it works: If the trial shows LBL-024 improves disease control or safety, the company could have a promising product for a niche cancer, which might attract partners or support further development.

If it fails: The trial could fail to show benefit or cause unexpected side effects, which would set the company back. Many cancer drugs do not succeed in trials, so a negative result is a real possibility.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 178 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll, and sign the written informed consent. 2. aged 18-75 years (including borderline values) at the time of signing the informed consent form 3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1. 4. The expected survival time is at least 12 weeks. 5. According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours），the subjects enrolled have at least one measurable target lesion. 6. Fertile men and women of childbearing age are willing to take effective contraceptive measures from the signing of the informed consent form to 6 months after the last dose of the investigational drug; women of childbearing age include premenopausal women and women who had menopause less than two years ago. Blood pregnancy test results must be negative for women of childbearing age within 7 days prior to the initial dose of the investigational drug. Exclusion Criteria: 1. Subjects who underwent major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to the initial use of the investigational drug, or require elective surgery during the trial period 2. Use of immunomodulatory drugs within 14 days prior to the initial use of the investigational drug, including but not limited to thymosin, interleukin, and interferon 3. Subjects with an active infection that currently requires intravenous anti-infective therapy. 4. Clinically uncontrollable pleural effusion, pericardial effusion, and requiring repeated drainage or medical intervention. 5. medical history of immunodeficiency including HIV antibody positive. 6. Pregnant or lactating women. 7. The investigator believes that the subject has other conditions that may affect compliance or that are not suitable for participating in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced neuroendocrine carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced neuroendocrine carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    25 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Anhui Cancer Hospital

    RECRUITING

    Hefei, Anhui, 230031, China

  • Anhui Provincial Hospital

    RECRUITING

    Hefei, Anhui, 230001, China

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

  • Beijing GoBroad Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100070, China

  • Chongqing University Cancer Hospital

    RECRUITING

    Chongqing, Chongqing Municipality, 400030, China

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350014, China

  • Guangxi Medical University Cancer Hospital

    RECRUITING

    Nanning, Guangxi, 530021, China

  • Harbin Medical University Cancer Hospital

    RECRUITING

    Harbin, Heilongjiang, 150081, China

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, 450008, China

  • Hubei Cancer Hospital

    RECRUITING

    Wuhan, Hubei, 430079, China

  • Liaoning Cancer Hospital

    RECRUITING

    Shenyang, Liaoning, 110801, China

  • Qilu Hospital of Shandong University

    RECRUITING

    Jinan, Shandong, 250063, China

  • Shandong Cancer Hospital

    RECRUITING

    Jinan, Shandong, 250117, China

  • Shanxi Cancer hospital

    RECRUITING

    Taiyuan, Shanxi, 030013, China

  • Sir Run Run Shaw Hospital，Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310016, China

  • Sun Yat-sen University Cancer Center (SYSUCC)

    RECRUITING

    Guangzhou, Guangdong, 510060, China

  • The First Affiliated Hospital Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

  • The First Affiliated Hospital of Guangdong Pharmaceutical University

    RECRUITING

    Guangzhou, Guangdong, 510080, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    RECRUITING

    Luoyang, Henan, 471003, China

  • The First Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, 330006, China

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610044, China

  • Xiangyang Central Hospital

    RECRUITING

    Xiangyang, Hubei, 441000, China

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.